Catalio Capital Closes $400M+ Fund IV

Catalio Capital Management Closes $400 Million Fund IV

Catalio Capital Management, a venture capital firm, has announced the successful completion of its fourth fund, exceeding $400 million. This closing was initially reported by Bloomberg.

The firm will maintain its investment strategy, focusing on companies operating within the healthcare and biotechnology sectors.

Investment Activity and Portfolio

Established in 2020, Catalio has already executed over 100 investment deals, as indicated by data from PitchBook.

Fund IV has already provided capital to 16 companies. These include PinkDx, a diagnostics innovator, and Superluminal Medicines, a company focused on drug discovery.

According to information shared with TechCrunch, the fund aims to complete a minimum of 30 investments.

The average investment size is projected to be $15 million per company.

Prior Funding Rounds

Catalio previously secured $381 million for Fund III in 2020 and $100 million for Fund II in 2019, according to PitchBook’s records.

Biotech Market Conditions

The biotechnology market has experienced a slowdown in venture funding over the past year.

This downturn coincides with rising interest rates and a less active initial public offering (IPO) landscape.

Total market funding reached only $12 billion in the previous year, a significant decrease from the high of $152.3 billion recorded in 2023, as detailed in a Bloomberg report.

This article has been updated to include further details regarding Fund IV.